Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021

Preclinical studies support the concept that inhibition of protein kinase C (PKC) by tamoxifen (TAM) should provide both antineoplastic effects and radiosensitization. High-dose TAM (80 mg/m(2) p.o. daily in divided doses) was given with and after conventional radiotherapy (XRT) to inhibit PKC-media...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Robins, H. Ian, Won, M., Seiferheld, Wendy F., Schultz, Christopher J., Choucair, Ali K., Brachman, David G., Demas, William F., Mehta, Minesh P.
Формат: Artigo
Язык:Inglês
Опубликовано: Duke University Press 2006
Предметы:
Clinical Investigations
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC1871929/
https://ncbi.nlm.nih.gov/pubmed/16443947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1215/S1522851705000311
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы